Leqembi
EMA Reverses Decision, Recommends Approval of Lecanemab (Leqembi) for Early Alzheimer’s Disease in Specific Patient Group
Lecanemab, Leqembi, Alzheimer’s disease, EMA, CHMP, early Alzheimer’s disease, ApoE ε4, amyloid-beta monoclonal antibody
Eisai Slashes Leqembi Sales Forecast Amid Continued Launch Challenges
Eisai, Leqembi, Alzheimer’s disease, sales forecast, revenue expectations, Biogen, pharmaceutical industry
Biogen Raises Profit Guidance Amid Leqembi Growth and MS Sales Decline
Biogen, profit guidance, Leqembi, multiple sclerosis, earnings report, pharmaceutical industry
Leqembi’s Global Sales Reach $67 Million, Yet US Adoption Faces Hurdles
Leqembi, Biogen, Eisai, Alzheimer’s disease, global sales, US adoption challenges
UK Approves Leqembi for Alzheimer’s, but NICE Deems It Too Costly for NHS Use
Leqembi, Alzheimer’s disease, NICE, NHS, cost-effectiveness, UK approval
Leqembi, Biogen and Eisai’s Alzheimer’s Drug, Gains UK Approval but Faces Cost-Effectiveness Hurdle
Leqembi, Alzheimer’s disease, UK approval, NICE, cost-effectiveness, Biogen, Eisai
Accelerating Sales of Eisai and Biogen’s Alzheimer’s Drug Leqembi in Japan
Leqembi, Alzheimer’s drug, Eisai, Biogen, Japan, sales acceleration
Biogen Lifts Outlook as Leqembi Sales Accelerate in Q2
Biogen, Leqembi, Q2 earnings, Alzheimer’s drug, cost cuts, profit outlook
Biogen Retains Biosimilars as Eisai-Partnered Leqembi Advances Amid Business Shift
Biogen, biosimilars, Leqembi, Eisai, Alzheimer’s disease, business pivot, pharmaceuticals, biotechnology
Eisai’s Alzheimer’s Drug Leqembi Shows Long-Term Benefits, Despite Study Limitations
Eisai, Leqembi, Alzheimer’s drug, long-term benefits, study limitations, cognitive decline, amyloid plaques, Biogen